Early outpatient follow‐up and 30‐day outcomes in patients hospitalized with cirrhosis

Fasiha Kanwal, Steven M. Asch, Jennifer R. Kramer, Yumei Cao, Sumeet Asrani, Hashem B. El‐Serag – 17 March 2016 – Preventing readmission has been the focus of numerous quality improvement efforts across many conditions. Early outpatient follow‐up has been proposed as the best mechanism for reducing readmissions. The extent to which early outpatient follow‐up averts readmission or improves outcomes in cirrhosis is not known. We evaluated the relationship between early outpatient follow‐up and short‐term readmission and mortality in patients with cirrhosis.

Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro

Quan Rao, Bingfeng Zuo, Zhen Lu, Xianjun Gao, Abin You, Chenxuan Wu, Zhi Du, HaiFang Yin – 17 March 2016 – Hepatocellular carcinoma (HCC) remains a global challenge due to high morbidity and mortality rates and poor response to treatment. Immunotherapy, based on introduction of dendritic cells (DCs) activated by tumor cell lysates as antigens ex vivo, shows limited response rates in HCC patients. Here, we demonstrate that tumor cell–derived exosomes (TEXs), displaying an array of HCC antigens, can elicit a stronger immune response than cell lysates in vitro and in vivo.

Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension

Julien Bissonnette, Juan Carlos Garcia‐Pagán, Agustín Albillos, Fanny Turon, Carlos Ferreira, Luis Tellez, Jean‐Charles Nault, Nicolas Carbonell, Jean‐Paul Cervoni, Mohamed Abdel Rehim, Annie Sibert, Louis Bouchard, Pierre Perreault, Jonel Trebicka, Félix Trottier‐Tellier, Pierre‐Emmanuel Rautou, Dominique‐Charles Valla, Aurélie Plessier – 17 March 2016 – Idiopathic noncirrhotic portal hypertension is a heterogeneous group of diseases characterized by portal hypertension in the absence of cirrhosis.

Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy

Amanda M. Lynn, Siddharth Singh, Stephen E. Congly, Disha Khemani, David H. Johnson, Russell H. Wiesner, Patrick S. Kamath, James C. Andrews, Michael D. Leise – 11 March 2016 – Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE.

Subscribe to